Oxford Biomedica plc (OXBDF) Q4 2025 Earnings Call Transcript

TL;DR

Key Points - Oxford Biomedica reported 2025 revenue up 33% at constant currency to GBP 170.9m and a return to operating EBITDA profitability at GBP 8.1m (underlying GBP 3.3m excluding one-offs), with backlog and contracted orders rising to GBP 204m and GBP 224m and year-end cash of GBP 96.9m. - The company completed an acquisition of an FDA‑approved commercial viral vector facility in Durham, North Carolina, adding integrated drug‑substance and fill‑and‑finish capacity (two GMP suites and one fill line) to accelerate U.S. commercial AAV manufacturing and local supply‑chain resilience.